Bunsod ng natuklasang mga nakabinbing drug applications, inirekomenda ng Anti-Red Tape Authority (ARTA) na kasuhan ng Office of the Ombudsman ang opisyal ng Food and Drug Administration–Center for Drug Regulation and Research (FDA–CDRR).
Sa motu propio disposition ng ARTA, inirekomenda nito ang 412 counts ng hindi pagtupad sa tungkulin sa kaukulang panahon sa ilalim ng Section 21 (e) of the Republic Act No. 11032 o ang Ease of Doing Business and Efficient Government Service Delivery Act of 2018 laban kay FDA – CDRR Director Jesusa Joyce N. Cirunay.
“Cursory perusal of Respondent Director Cirunay’s attachment in both her Letters would show that there has been a delay in the processing of the Four Hundred and Twelve (412) applications. In fact, none of the applications met the mandate of R.A. No. 11032, specifically as to processing time,” giit ng ARTA.
Sa imbestigasyon ng ARTA, may mga nakabinbing AR drug applications mula pa noong 2014.
Magpinsang paslit nagkayayaang maligo sa lawa, nalunod
Napag-alam din na walo pa ang nakabinbing AR applications ayon sa Philippine Chamber of Pharmaceutical Industry, Inc. (PCPI) na unang iginiit ni Cirunay na iisa na lamang.
“In view of the foregoing facts, this Complaint-Affidavit is filed for the purpose of initiating the necessary action against Jesusa Joyce N. Cirunay, Director IV of the FDA-CDRR, and for other appropriate crimes as the Honorable Ombudsman may see fit and proper to indict respondent,” dagdag ng ARTA.
Beth Camia
